Colgate-Palmolive stock (US1941621039): Shareholders approve board, pay and auditor at 2026 AGM

Colgate-Palmolive stockholders overwhelmingly backed all director nominees, executive pay and PwC as auditor at the 2026 annual meeting, while rejecting DEI and independent chair proposals.

Colgate-Palmolive held its 2026 annual stockholders meeting recently, where investors elected all 11 director nominees, ratified PricewaterhouseCoopers LLP as the independent auditor for the year ending December 31, 2026, and approved the non-binding say-on-pay resolution on executive compensation, according to the company's 8-K filing as of May 2026. Stockholders rejected two proposals: one to remove DEI criteria from board candidate considerations and another for an independent board chairman.

The auditor ratification passed with 647,385,500 votes in favor and 53,015,911 against. The say-on-pay vote saw 591,185,556 for and 43,039,011 against. The DEI proposal garnered just 14,002,273 votes for versus 618,251,142 against, while the independent chairman proposal received 182,439,869 for and 452,415,385 against, per the same SEC filing.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Colgate-Palmolive
• Sector/industry: Consumer Staples / Oral Care
• Headquarters/country: United States
• Core markets: Global, with strong US presence
• Key revenue drivers: Toothpaste, oral care products
• Home exchange/listing venue: NYSE (CL)
• Trading currency: USD

Colgate-Palmolive: core business model

Colgate-Palmolive is a leading global consumer products company focused primarily on oral, personal and home care, pet nutrition, and flavorings. Its flagship Colgate brand dominates the oral care category worldwide, with toothpaste holding significant market share in the US and emerging markets. The company operates through two main segments: Oral, Personal and Home Care, and Pet Nutrition under the Hill's brand.

Revenue is generated via a portfolio of trusted brands sold in over 200 countries. In the US, Colgate-Palmolive benefits from strong brand loyalty and recurring demand for essentials like toothpaste and mouthwash, making it a staple for retail investors seeking defensive consumer staples exposure.

Main revenue and product drivers for Colgate-Palmolive

Oral care accounts for the majority of sales, with Colgate toothpaste as the top driver. Key products include Colgate Total, Optic White and Max Fresh, which cater to whitening, sensitivity and daily hygiene needs. Personal care brands like Palmolive dish soap and Speed Stick deodorants contribute steadily, while Hill's pet nutrition targets premium veterinary-recommended pet food.

Geographically, North America represents a core market, with the US driving consistent growth through e-commerce and big-box retail channels. Emerging markets fuel expansion via affordable formats, supporting overall revenue stability for US-listed shares.

Industry trends and competitive position

The consumer staples sector emphasizes resilience amid economic cycles, with oral care proving recession-resistant. Colgate-Palmolive holds a commanding position against rivals like Procter & Gamble and Unilever, leveraging innovation in natural ingredients and sustainability. Recent trends include premiumization and digital marketing to younger US consumers.

Why Colgate-Palmolive matters for US investors

As a NYSE-listed blue-chip with decades of dividend growth, Colgate-Palmolive offers US investors exposure to a defensive powerhouse intertwined with the American economy. Its US manufacturing and R&D facilities underscore domestic relevance, while global diversification mitigates risks.

Conclusion

Colgate-Palmolive's 2026 AGM reflected strong shareholder alignment with management on governance and compensation, signaling confidence in the board's strategy. With robust support for key resolutions and rejection of alternatives, the company maintains its focus on core operations. Investors will watch upcoming quarters for execution amid staples sector dynamics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.